linjc16/ctgov huggingface dataset:
Application of Deep-learning and Ultrasound Elastography in Opportunistic Screening of Breast Cancer

Study Overview
=================
Brief Summary
-----------------
As the most common cancer expected to occur all over the world, breast cancer still faces with the unsatisfied diagnostic accuracy in US imaging. S-detect is a sophisticated CAD system for breast US imaging based on deep learning algorithms. E-breast is a software installed in US machines which automatically reveals tumor elastographic features. This multi-center study intends to further validate the diagnostic efficiency of S-detect and E-breast in opportunistic breast cancer screening populations in China. Our hypothesis is that S-detect and E-breast can increase the diagnostic accuracy and specificity as compared to routinely US examinations by doctors.

Official Title
-----------------
A Multi-center Study of Deep Learning Diagnosis and Ultrasound Elastography in Opportunistic Screening of Breast Cancer

Conditions
-----------------
Breast Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female over 18 years of age; Had breast lesions detected by ultrasound. No clinical symptoms such as nipple discharge, while breast lesions were not palpable. Received breast surgery within one week of ultrasound examination. Agreed to participant in this study and signed informed consent. Exclusion Criteria: Patients who had received a biopsy of breast lesion before the ultrasound examination. Patients who were pregnant or lactating. Patients who were undergoing neoadjuvant treatment.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Benign or malignant lesions as determined by pathology | The pathological diagnosis of benign or malignant lesions from surgery samples | From 2019.1.1 to 2020.1.1 |
Study of Patients With Chronic Hepatitis C Infected With HCV LVL G1 and Effect of Peg-Intron Plus Rebetol Treatment (Study P04793)

Study Overview
=================
Brief Summary
-----------------
To determine the relapse rate at 24 weeks follow up in Hepatitis C Virus Genotype 1 Low Viral Load (HCV LVL G1) patients treated for 24 weeks with Peg Intron and Rebetol who are Hepatitis C Virus-Ribonucleic Acid (HCV-RNA) negative at treatment week 4 and week 24. To determine the proportion of patients (%) with sustained virological response at 24 weeks post follow up treatment.

Detailed Description
-----------------
Approximately 500 patients from about 100 sites to be identified as HCV LVL G1 patients

Official Title
-----------------
PREDICT - Prospective Observational Study Of A Cohort Of Naïve Patients With Chronic Hepatitis C Infected With Hepatitis C Virus Genotype 1 Low Viral Load (HCV LVL G1) And Treated With Peg-Intron 1.5 ug/Kg/Week Plus Rebetol 800-1200 mg/Day Who Achieved A Negative HCV-RNA At Week 4 and at Week 24

Conditions
-----------------
Hepatitis C

Intervention / Treatment
-----------------
* Drug: PegIntron
* Drug: Rebetol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Willingness to participate 18 years or older, either gender, any race Must have Hepatitic C Virus Low Viral Load [LCV LVL] (positive, but <600,000 IU/mL on the assay used by the individual study site. Only Hepatitis C Virus-Ribonucleic acid/quantitative polymerase chain reaction [HCV-RNA/qPCR] assays with results in IU/ml are acceptable) AND been diagnosed with Genotype 1 Subject considered suitable for treatment per local label Investigator considers suitable and subject consents to be treated Exclusion Criteria: Does not show negative polymerase chain reaction [PCR] at week 4 Pregnant women or those who plan to become pregnant or sexual partners of women who plan to become pregnant Subject does not qualify based on contra-indication, special warning, special population, and/or pregnancy & lactation section of the Summary of Product Characteristics [SmPC]

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| PegIntron plus Rebetol<br>Those with chronic Hepatitis C infected with HCV LVL G1 | Drug: PegIntron<br>* 1.5 ug/kg/week<br>* Other names: SCH 054031;Drug: Rebetol<br>* 800-1200 mg/day<br>* Other names: SCH 18908;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of HCV LVL G1 Participants Who Relapsed | Relapse was defined as undetectable Hepatitis C virus-ribonucleic acid (HCV-RNA) at End of Treatment, but detectable HCV-RNA at Follow-up Week 24. | Week 24 of follow-up |
Prospective Study Of A Size Tailored Approach To Repair Umbilical And Epigastric Primary Ventral Hernias

Study Overview
=================
Brief Summary
-----------------
Primary ventral hernias, such as umbilical and epigastric hernias, are best repaired with abdominal wall reinforcement by mesh implantation. Mesh-devices using a dual-sided mesh technology have been developed for the specific indication of small ventral hernias; this technique is very attractive because the mesh can be introduced through a nearly invisible scar in the umbilicus. The dual layer of the mesh inhibits the formation of adhesions of the viscera to the mesh so, if wanted, it can be positioned in a intraperitoneal position. No literature is available on the adequate size of mesh needed to repair a hernia defect of an umbilical or epigastric hernia. Very small hernias are now often enlarged for repair with a large mesh device. Small hernias might benefit of repair with a small mesh device so no enlargement of the defect is necessary Larger hernias might benefit from a larger mesh size to have more overlap of the mesh beyond the hernia defect. With this prospective cohort study the investigators want to explore the efficacy of C-QUR V-Patch of different sizes for the different sizes of hernia defects.

Official Title
-----------------
Prospective Observational Cohort Study Of A Size Tailored Approach To Repair Umbilical And Epigastric Primary Ventral Hernias

Conditions
-----------------
Ventral Hernia, Umbilical Hernia, Epigastric Hernia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all adult patients that are planned for surgical repair of a primary umbilical or epigastric hernia will be considered to enter the study. Exclusion Criteria: patients refusing to participate at the follow up visits pregnancy age < 18 years life expectancy less than 12 months recurrent umbilical or epigastric hernia incisional or trocar site hernias emergency operations liver cirrhosis or ascites cancer patients concomitant surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
dual sided mesh, primary ventral hernia repair with mesh, umbilical hernia repair, epigastric hernia repair, C-Qur V-patch, Size tailored repair, preperitoneal repair, abdominal hernia
Daily Monitoring of Exhaled Nitric Oxide in Asthmatic Patients

Study Overview
=================
Brief Summary
-----------------
Previous studies have demonstrated that exhaled nitric oxide can be useful to monitor the efficacy of anti-inflammatory treatment as well as to predict a risk of asthma relapse in asthmatic patients. The aim of the present study is to evaluate the time course of exhaled nitric oxide in mild asthmatic patients, stopping regular treatment with inhaled corticosteroids, if it is possible, in relationship with symptoms and lung function.

Detailed Description
-----------------
All patients were evaluated with pulmonary lung function, exhaled nitric oxide and peak expiratory flow (PEF) and fill in a personal diary for the first two weeks when patients are in treatment; the same evaluation will be made for other four weeks without treatment.

Official Title
-----------------
Daily Monitoring of Exhaled Nitric Oxide in Asthmatic Patients Stopping Anti-inflammatory Treatment

Conditions
-----------------
Asthma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: mild asthmatic treated with low dose inhaled steroids for whom it has to be considered stop of steroid treatment according to GINA guidelines Exclusion Criteria: age < 5 years chronic respiratory diseases

Ages Eligible for Study
-----------------
Minimum Age: 5 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
asthma, exhaled nitric oxide, lung function
Oral Trehalose Therapy to Reverse Arterial Aging in Middle-Aged and Older Adults

Study Overview
=================
Brief Summary
-----------------
The proposed study will assess the ability of a naturally occurring sugar to improve the function of arteries with age. Overall, the proposed research project has the long-term potential to influence clinical practice guidelines by establishing a novel, easy to deliver, cost-effective therapy for treating age-associated arterial dysfunction and reducing the risk of cardiovascular disease with age.

Official Title
-----------------
Oral Trehalose Therapy to Reverse Arterial Aging in Middle-Aged and Older Adults

Conditions
-----------------
Vascular Aging

Intervention / Treatment
-----------------
* Drug: Placebo
* Drug: High-dose trehalose


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: women must be postmenopausal body mass index (BMI) <40 kg/m2 weight stable in the prior 3 months absence of clinical disease as determined by medical history, physical examination, blood and urine chemistries, ankle-brachial index, and a graded exercise stress test with monitoring of blood pressure and 12-lead ECG

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 79 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Maltose<br> | Drug: Placebo<br>* 100g maltose 1/day<br>|
| Experimental: High-dose trehalose<br> | Drug: High-dose trehalose<br>* 100g 1/day<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Arterial Stiffness | Arterial pulse wave velocity | 12 weeks | 
| nitric-oxide mediated endothelium-dependent dilation | flow-mediated dilation and forearm blood flow responses to acetylcholine in the presence and absence of N'-monomethyl-L-arginine | 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Systemic oxidative stress and inflammation | circulating markers of oxidative stress and inflammation | 12 weeks | 
| Endothelial cell oxidative stress and inflammation | inflammatory and oxidative stress markers in biopsied vascular and arterial endothelial cells | 12 weeks | 
| Insulin sensitivity | intravenous glucose tolerance test | 12 weeks | 
| Endothelial cell autophagic flux |  | 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
arterial function, cardiovascular, aging, endothelial function, arterial stiffness, vascular function, Trehalose
Totally Laparoscopic Distal Gastrectomy for Gastric Cancer

Study Overview
=================
Brief Summary
-----------------
This study was designed as a randomized clinical trial comparing the totally laparoscopic distal gastrectomy with laparoscopy-assisted distal gastroectomy for patients with gastric cancer, in terms of short-term and long-term outcomes.

Detailed Description
-----------------
When one patient was enrolled, he will be randomly divided into experimental group (totally laparoscopic distal gastrectomy) or control group (laparoscopy-assisted distal gastrectomy). When he receives surgery, intraoperative parameters would be recorded. when the patient discharges, the routine follow-up would be regularly performed for the survival.

Official Title
-----------------
Randomized Controlled Trial Comparing the Outcomes of Totally Laparoscopic Distal Gastrectomy and Laparoscopy-assisted Gastrectomy for Gastric Cancer

Conditions
-----------------
Postoperative Complications

Intervention / Treatment
-----------------
* Procedure: totally laparoscopic distal gastrectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: aged 18-80 years old, no gender limitation; primary gastric cancer and planed for distal gastrectomy; Exclusion Criteria: patients with total or proximal gastrectomy; patients with distant metastasis.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: totally laparoscopic distal gastrectomy<br>patients in this arm will receive totally laparoscopic distal gastrectomy | Procedure: totally laparoscopic distal gastrectomy<br>* all the surgical procedure would be finished under laparoscopy<br>|
| No Intervention: laparoscopy-assisted distal gastrectomy<br>patients in this group will receive laparoscopy-assisted distal gastrectomy | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| postoperative stay | the time from the finish of surgery to discharge | about one week to one month from the finish of surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Survival | the survival rate at the third year from the finish of surgery | 3 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
laparoscopy-assisted gastrectomy, totally laparoscopic gastrectomy, distal gastroectomy, postoperative hospital stay, survival, complications
An Open Parallel Study to Determine the Optimum Dosing Schedule for AS-101 in AIDS/ARC Patients

Study Overview
=================
Brief Summary
-----------------
To compare AS-101 dosing schedules (once a week; 3 times a week; 5 times a week; or 5 times per week on alternate weeks) on the effect on clinical immunology and virus burden in AIDS or AIDS related complex (ARC) patients.

Official Title
-----------------
An Open Parallel Study to Determine the Optimum Dosing Schedule for AS-101 in AIDS/ARC Patients

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Drug: AS-101


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Concurrent Medication: Allowed: Standard therapy for infections. Acyclovir. Ganciclovir. Allowed only with permission of Wyeth-Ayerst medical monitor: Zidovudine (AZT). Immunomodulators. Specific therapy for malignancies (including Kaposi's sarcoma). Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: Evidence of severe liver dysfunction (serum albumin < 3 g/dl, SGOT or SGPT > 5 x upper limit of normal, prothrombin time > 15 seconds), or gastrointestinal, renal, respiratory, endocrine, hematologic, cardiovascular system abnormalities or psychiatric disorder other than abnormalities secondary to AIDS or AIDS related complex (ARC). Evidence of AIDS-related central nervous system involvement. Disseminated Kaposi's sarcoma. Concurrent Medication: Excluded without permission of Wyeth-Ayerst medical monitor: Zidovudine (AZT). Immunomodulators. Specific therapy for malignancies (including Kaposi's sarcoma). Patients with the following are excluded: Evidence of major system abnormalities other than abnormalities secondary to AIDS or AIDS related complex. Concomitant conditions as specified in Patient Exclusion Co-existing Conditions. Unlikely or unable to comply with the requirements of the protocol. Prior Medication: Excluded within 4 weeks of study entry: Systemic antiviral agents. Immunosuppressive agents. Immune stimulators such as BCG vaccine, isoprinosine, or other immunomodulators. Patients must: Have a diagnosis of AIDS or AIDS related complex (ARC). Demonstrate intolerance or refusal to take zidovudine (AZT). Provide written informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: AS-101|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Drug Therapy, Combination, Acquired Immunodeficiency Syndrome, AIDS-Related Complex, ammonium trichloro(dioxoethylene-O,O'-)tellurute
Kinematic Parameters of Running in Individuals With Pronated Foot

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to examine the kinematic parameters of individuals with pronated foot compared with individuals with normal foot

Detailed Description
-----------------
Individual with and without pronated foot will be recruited. Pronation will be defined according to navicular drop test. Inclusion criteria : individual who run on a regular basis at least 3 times per week for one hour, can run 5 Km in less then 40 minutes, without past injuries during the last year of Achilles tendon or other lower extremities pain. Individuals will be asked to run for 5 Km in self selected velocity. The Milestone pod device will be used to monitor kinematic parameters. functional test will be conducted before and after the running as follows: heel raise test and one leg hop for distance test.

Official Title
-----------------
Kinematic Parameters of Running in Individuals With Pronated Foot

Conditions
-----------------
Pronation; Ankle

Intervention / Treatment
-----------------
* Diagnostic Test: running


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: running on a daily basis at least 3 times per week with minimum of 1 hour capable to run 5 km in less then 40 minutes willing to participate in the study Exclusion Criteria: previous surgery in lower extremities Achilles tendon pain during the last year

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: two groups. Individuals with and without pronated foot.
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: pronated group<br>individuals with pronated foot | Diagnostic Test: running<br>* individuals will be asked to run for 5 km in self selected speed<br>* Other names: kinematic parameters of running;|
| Active Comparator: control group<br>individuals with normal foot posture | Diagnostic Test: running<br>* individuals will be asked to run for 5 km in self selected speed<br>* Other names: kinematic parameters of running;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| stride length | stride length in cm | up to 6 months | 
| cadence | steps per minute | up to 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| velocity | running velocity in Km/hour | up to 6 months | 
| heel raise test | how many good heel raise till fatigue | up to 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
foot posture, running, foot index